Staphylococcal Infections¶
Chapter 152 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Staphylococcus aureus is a versatile pathogen causing a wide range of infections from mild skin infections to life-threatening systemic diseases.
- Community-acquired methicillin-resistant S. aureus (CA-MRSA) has emerged as a significant public health threat, particularly in healthcare settings and among high-risk populations.
- Antimicrobial resistance, especially to β -lactams and glycopeptides, is widespread, necessitating tailored antibiotic selection based on susceptibility testing.
- Toxin-mediated diseases like toxic shock syndrome (TSS) and staphylococcal scalded skin syndrome (SSSS) require prompt recognition and supportive management.
- Prevention strategies include decolonization with mupirocin and chlorhexidine, along with strict infection control measures in healthcare settings.
1. DEFINITION & OVERVIEW¶
Staphylococcus aureus is a gram-positive cocci, a leading cause of healthcare-associated infections. It exhibits both commensal and opportunistic behavior, colonizing skin, mucosal surfaces, and medical devices. The organism's versatility is underscored by its ability to cause a spectrum of infections, from superficial skin lesions to severe systemic diseases. The rise of methicillin-resistant S. aureus (MRSA) has significantly impacted clinical management, necessitating advanced diagnostic and therapeutic approaches.
Table 152-1 Common Illnesses Caused by Staphylococcus aureus¶
| Clinical Syndrome | Description |
|---|---|
| Skin and Soft Tissue Infections | Folliculitis, abscess, furuncle, carbuncle, cellulitis, impetigo, mastitis, surgical wound infections |
| Musculoskeletal Infections | Septic arthritis, osteomyelitis, pyomyositis, psoas abscess |
| Respiratory Tract Infections | Ventilator-associated pneumonia, septic pulmonary emboli, postviral pneumonia, empyema |
| Bacteremia and Sepsis | Sepsis, septic shock, metastatic foci of infection (kidney, joints, bone, lung) |
| Infective Endocarditis | Native-valve and prosthetic-valve endocarditis, especially in injection drug users |
| Toxin-Mediated Illnesses | Toxic shock syndrome (TSS), staphylococcal scalded skin syndrome (SSSS), food poisoning |
1.1 Microbiology and Taxonomy¶
S. aureus is a gram-positive cocci in the family Micrococcaceae, forming grapelike clusters on Gram’s stain. It is catalase-positive, nonmotile, and capable of prolonged survival on environmental surfaces. The organism is distinguished by coagulase production, which differentiates it from other staphylococcal species. S. aureus ferments mannitol, produces DNAse, and is positive for protein A.
1.2 Virulence Factors¶
S. aureus employs a range of virulence factors, including toxins ( α -toxin, Panton-Valentine leukocidin), adhesins (MSCRAMMs), and biofilm formation. These factors contribute to its pathogenicity, enabling tissue invasion, immune evasion, and resistance to antimicrobial agents.
2. EPIDEMIOLOGY¶
S. aureus is a common commensal in the nasal passages and skin, with 20–40% of healthy individuals colonized. Colonization rates are higher in diabetics, HIV-infected patients, and those with skin damage. MRSA has become a significant cause of healthcare-associated infections, with 40–50% of S. aureus isolates in U.S. hospitals resistant to methicillin. Risk factors include immunocompromise, healthcare exposure, and poor hygiene.
2.1 Demographics¶
S. aureus infections are more prevalent in males, individuals with diabetes, and those with chronic skin conditions. MRSA outbreaks are common in correctional facilities, athletic settings, and among injection drug users. Neonatal infections, particularly staphylococcal scalded skin syndrome (SSSS), are most common in infants.
2.2 Geographical Distribution¶
CA-MRSA strains like USA300 are prevalent in the U.S., while other clones dominate in Europe and Asia. Global spread of MRSA is linked to travel, healthcare tourism, and antibiotic misuse. S. aureus is a leading cause of healthcare-associated infections, particularly in intensive care units.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
S. aureus causes infections through direct tissue invasion, toxin production, and immune evasion. The organism's ability to form biofilms on medical devices and resist antimicrobial agents contributes to persistent infections. MRSA resistance is mediated by the mecA gene, which encodes PBP2a, altering penicillin-binding activity. Toxin-mediated diseases like TSS and SSSS result from superantigen activity, leading to systemic inflammation and skin desquamation.
Table 152-2 Case Definition of Staphylococcus aureus Toxic Shock Syndrome¶
| Clinical Criteria | Laboratory Criteria |
|---|---|
| Fever ‡102.0°F | Negative blood or CSF cultures for other pathogens |
| Diffuse macular erythroderma | Serologic tests negative for Rocky Mountain spotted fever, leptospirosis, or measles |
| Desquamation 1–2 weeks after rash onset | Case Classification: Probable (4/5 criteria) or Confirmed (all 5 criteria) |
| Hypotension (systolic £90 mmHg in adults) | Desquamation (unless death occurs before) |
| Multisystem involvement (‡3 organ systems) | — |
3.1 Toxin Production¶
S. aureus produces exotoxins ( α -toxin, TSST-1, enterotoxins) and exfoliative toxins (ETA, ETB). These toxins mediate tissue damage, systemic inflammation, and immune dysregulation. TSST-1 is a key virulence factor in TSS, while exfoliative toxins cause epidermal separation in SSSS.
3.2 Resistance Mechanisms¶
MRSA resistance is due to the mecA gene, which encodes PBP2a, reducing β -lactam binding. Vancomycin resistance (VRSA) involves vanA gene-mediated thickening of peptidoglycan. Resistance to other antibiotics (aminoglycosides, fluoroquinolones) is common, driven by horizontal gene transfer and mutation.
4. CLINICAL FEATURES¶
Clinical manifestations vary by infection type. Skin and soft tissue infections (SSTIs) present with abscesses, cellulitis, or furuncles. Systemic infections include sepsis, endocarditis, and osteomyelitis. Toxin-mediated diseases like TSS and SSSS are characterized by fever, rash, hypotension, and multisystem involvement. MRSA infections often present with severe, rapidly progressive symptoms, including necrotizing fasciitis and septic shock.
4.1 Skin and Soft Tissue Infections¶
Common SSTIs include folliculitis, abscesses, furuncles, carbuncles, and cellulitis. MRSA infections are often more severe, with rapid progression and systemic symptoms. Impetigo and surgical site infections are also prevalent, particularly in immunocompromised patients.
4.2 Systemic Infections¶
S. aureus can cause sepsis, endocarditis, and osteomyelitis. Endocarditis is more common in IV drug users and those with prosthetic valves. Osteomyelitis often follows hematogenous spread or contiguous infection, with fever, bone pain, and elevated inflammatory markers.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses for SSTIs include other bacterial infections (e.g., streptococcal cellulitis, fungal infections), viral exanthems, and non-infectious skin conditions. For TSS, differential diagnoses include sepsis, viral exanthems, and drug reactions. In endocarditis, differentiating S. aureus from other pathogens (e.g., Streptococcus species) is critical, especially in patients with prosthetic valves or IV drug use.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis is confirmed by Gram’s stain and culture of infected material. Blood cultures are essential for bacteremia. Molecular methods like PCR and MALDI-TOF mass spectrometry improve rapid identification. For TSS, clinical criteria (Table 152-2) and exclusion of other diagnoses are key. Imaging (MRI, CT) is critical for osteomyelitis and abscess localization.
6.1 Diagnostic Criteria¶
TSS diagnosis requires fever, rash, hypotension, multisystem involvement, and exclusion of other causes. SSSS is diagnosed by characteristic skin desquamation and exfoliative toxin-producing strains. Endocarditis is suspected by clinical findings (e.g., new murmurs) and imaging (echocardiography).
6.2 Laboratory Tests¶
Blood cultures, Gram’s stain, and PCR for S. aureus or MRSA are essential. Serologic tests for other pathogens (e.g., Rocky Mountain spotted fever) are used to rule out alternative diagnoses. Imaging (MRI, CT) helps localize abscesses and assess osteomyelitis.
7. MANAGEMENT & TREATMENT¶
Treatment involves source control (drainage, device removal) and antimicrobial therapy. MRSA infections require vancomycin, daptomycin, or linezolid. SSTIs may be managed with oral antibiotics, while severe infections require intravenous therapy. Prosthetic device infections often necessitate surgical intervention. Supportive care for TSS includes fluid resuscitation and corticosteroids.
Table 152-3 Antimicrobial Therapy for Staphylococcal Infections¶
| Sensitivity/Resistance | Drug of Choice | Alternatives | Comments |
|---|---|---|---|
| Sensitive to penicillin | Penicillin G (4 mU q4h) | Nafcillin, oxacillin, cefazolin | Fewer than 5% of isolates are sensitive to penicillin |
| Resistant to methicillin | Vancomycin (15–20 mg/kg q8–12h) | Daptomycin, linezolid, ceftaroline | Sensitivity testing required before selecting alternatives |
| Resistant to methicillin with intermediate vancomycin resistance | Daptomycin (6–10 mg/kg q24h) | Linezolid, ceftaroline, telavancin | Avoid in patients with renal disease |
| Resistant to methicillin with vancomycin resistance | Daptomycin (6–10 mg/kg q24h) | Linezolid, tedizolid | Vancomycin-resistant isolates reported |
7.1 Antimicrobial Therapy¶
For MRSA, vancomycin (15–20 mg/kg q8–12h) or daptomycin (6–10 mg/kg q24h) is recommended. Linezolid (600 mg q12h) and ceftaroline (600 mg q8–12h) are alternatives. For MSSA, β -lactams (e.g., nafcillin, cefazolin) are preferred. Duration of therapy varies by infection type (e.g., 4–6 weeks for endocarditis).
7.2 Surgical Intervention¶
Abscess drainage, debridement of necrotic tissue, and removal of infected prosthetic devices are critical. For osteomyelitis, surgical debridement is often required alongside antibiotics. Endocarditis may require valve replacement and prolonged antibiotic therapy.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis varies by infection severity and patient comorbidities. Complications include metastatic infections (e.g., septic arthritis, osteomyelitis), endocarditis, and septic shock. MRSA infections carry higher mortality rates due to resistance and aggressive disease. Early diagnosis and source control improve outcomes, particularly in immunocompromised patients.
8.1 Complications¶
S. aureus infections can lead to septic arthritis, osteomyelitis, endocarditis, and septic shock. Toxin-mediated diseases like TSS and SSSS may result in multiorgan failure. MRSA infections are associated with higher mortality due to resistance and rapid progression.
8.2 Mortality¶
Mortality is highest in septic shock, endocarditis, and invasive MRSA infections. Prosthetic valve endocarditis has a mortality rate of 20–40%. Early intervention and appropriate antimicrobial therapy are critical to improving survival.
9. SPECIAL CONSIDERATIONS¶
Pregnancy, pediatrics, and the elderly require tailored approaches. Neonatal SSSS is a medical emergency, while elderly patients are at higher risk for severe infections. Infection control measures are critical in healthcare settings to prevent MRSA transmission. Decolonization with mupirocin and chlorhexidine reduces recurrence rates in high-risk populations.
9.1 Pregnancy¶
S. aureus infections in pregnancy may complicate labor and delivery. Neonatal SSSS requires immediate treatment with antistaphylococcal antibiotics. Maternal infections can lead to preterm labor or sepsis.
9.2 Pediatrics¶
Children are at risk for SSSS, SSTIs, and osteomyelitis. MRSA infections in children often present with severe, rapidly progressive symptoms. Vaccination and hygiene education are critical for prevention.
10. KEY POINTS & CLINICAL PEARLS¶
- S. aureus is a leading cause of healthcare-associated infections, with MRSA posing significant therapeutic challenges due to resistance.
- Early recognition of toxin-mediated diseases (TSS, SSSS) and prompt supportive care are critical for survival.
- Antimicrobial selection should be guided by susceptibility testing, with vancomycin, daptomycin, and linezolid as first-line options for MRSA.
- Decolonization with mupirocin and chlorhexidine reduces recurrence in high-risk patients.
- Surgical intervention is often necessary for deep infections (e.g., osteomyelitis, prosthetic device infections).